Prescott Group Capital Management L.L.C. Takes Position in ClearPoint Neuro, Inc. $CLPT

Prescott Group Capital Management L.L.C. purchased a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 180,525 shares of the company’s stock, valued at approximately $2,470,000. Prescott Group Capital Management L.L.C. owned about 0.64% of ClearPoint Neuro at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Parsons Capital Management Inc. RI increased its stake in shares of ClearPoint Neuro by 3.1% in the 4th quarter. Parsons Capital Management Inc. RI now owns 147,186 shares of the company’s stock valued at $2,014,000 after acquiring an additional 4,450 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of ClearPoint Neuro by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 42,958 shares of the company’s stock valued at $936,000 after acquiring an additional 10,168 shares during the last quarter. Centaurus Financial Inc. bought a new stake in shares of ClearPoint Neuro in the 3rd quarter valued at about $196,000. Millennium Management LLC increased its stake in shares of ClearPoint Neuro by 88.0% in the 3rd quarter. Millennium Management LLC now owns 187,801 shares of the company’s stock valued at $4,092,000 after acquiring an additional 87,930 shares during the last quarter. Finally, Focus Partners Wealth increased its stake in shares of ClearPoint Neuro by 501.8% in the 3rd quarter. Focus Partners Wealth now owns 121,106 shares of the company’s stock valued at $2,639,000 after acquiring an additional 100,983 shares during the last quarter. 30.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on CLPT. B. Riley Financial upped their price target on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Stifel Nicolaus began coverage on ClearPoint Neuro in a research report on Friday, May 8th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, ClearPoint Neuro has a consensus rating of “Hold” and an average price target of $18.00.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $11.20 on Thursday. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79. The stock has a 50 day simple moving average of $10.55 and a 200 day simple moving average of $12.88. ClearPoint Neuro, Inc. has a 52-week low of $8.27 and a 52-week high of $30.10. The firm has a market capitalization of $335.89 million, a PE ratio of -11.09 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The business had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. Sell-side analysts predict that ClearPoint Neuro, Inc. will post -1.05 EPS for the current fiscal year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.